Samsung Biologics Co.,Ltd. is a prominent player in the Healthcare sector, specifically operating within the Biotechnology industry. The company boasts a massive market capitalization of 73.70 Trillion. Despite posting a positive 7-day performance of 5.01%, the stock has recently experienced a short-term pullback, dropping 2.03% over the last 24 hours to trade at a current price of KRW 1,592,000.00.

Based on our proprietary technical scoring system, Samsung Biologics earns a total score of -4, translating to a Strong Sell rating. This heavily bearish outlook is anchored by a negative trend score, as the current price rests notably below its 200-day Simple Moving Average (KRW 1,672,830). Downside momentum is further validated by a negative MACD histogram, reflecting a bearish crossover. Volume metrics confirm this downward pressure; the On-Balance Volume (OBV) sits below its 5-day SMA, indicating active distribution by sellers. Meanwhile, the ADX at 22.68 suggests the absence of a vigorous prevailing trend, and the RSI at 41.16 remains in neutral territory, meaning the stock has not yet reached oversold conditions to justify a potential rebound.

Looking at the broader fundamental context, this technical weakness aligns closely with concerning recent financial disclosures. Samsung Biologics reported an EPS of 930.21 alongside a massive negative earnings surprise of -7730.0%, suggesting a severe deviation from market expectations. Furthermore, traditional valuation metrics like the P/E ratio are currently unavailable, and the stock offers a dividend yield of 0%, providing no income buffer for investors. With the next earnings report scheduled distantly for 22/04/2026, there are few near-term fundamental catalysts on the horizon. Consequently, the convergence of technical breakdown and negative earnings shocks warrants extreme caution.